These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 25255039)
21. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity. Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331 [TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. D'Amore C; Di Leva FS; Sepe V; Renga B; Del Gaudio C; D'Auria MV; Zampella A; Fiorucci S; Limongelli V J Med Chem; 2014 Feb; 57(3):937-54. PubMed ID: 24387325 [TBL] [Abstract][Full Text] [Related]
23. Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists. Schmidt J; Schierle S; Gellrich L; Kaiser A; Merk D Bioorg Med Chem; 2018 Aug; 26(14):4240-4253. PubMed ID: 30026040 [TBL] [Abstract][Full Text] [Related]
24. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. Merk D; Steinhilber D; Schubert-Zsilavecz M Future Med Chem; 2012 May; 4(8):1015-36. PubMed ID: 22650242 [TBL] [Abstract][Full Text] [Related]
25. The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression. Bijsmans IT; Guercini C; Ramos Pittol JM; Omta W; Milona A; Lelieveld D; Egan DA; Pellicciari R; Gioiello A; van Mil SW Sci Rep; 2015 Sep; 5():14086. PubMed ID: 26369990 [TBL] [Abstract][Full Text] [Related]
26. Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation. Gioiello A; Cerra B; Mostarda S; Guercini C; Pellicciari R; Macchiarulo A Curr Top Med Chem; 2014; 14(19):2159-74. PubMed ID: 25388535 [TBL] [Abstract][Full Text] [Related]
28. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease. Yu DD; Andrali SS; Li H; Lin M; Huang W; Forman BM Bioorg Med Chem; 2016 Sep; 24(18):3986-3993. PubMed ID: 27372840 [TBL] [Abstract][Full Text] [Related]
29. Allosteric modulation of the farnesoid X receptor by a small molecule. Gabler M; Kramer J; Schmidt J; Pollinger J; Weber J; Kaiser A; Löhr F; Proschak E; Schubert-Zsilavecz M; Merk D Sci Rep; 2018 May; 8(1):6846. PubMed ID: 29717168 [TBL] [Abstract][Full Text] [Related]
30. Structure-activity relationship of bile alcohols as human farnesoid X receptor agonist. Iguchi Y; Kihira K; Nishimaki-Mogami T; Une M Steroids; 2010 Jan; 75(1):95-100. PubMed ID: 19913569 [TBL] [Abstract][Full Text] [Related]
31. Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor. Fang Y; Hegazy L; Finck BN; Elgendy B J Med Chem; 2021 Dec; 64(24):17545-17571. PubMed ID: 34889100 [TBL] [Abstract][Full Text] [Related]
32. N Masuda A; Gohda K; Iguchi Y; Fujimori K; Yamashita Y; Oda K; Une M; Teno N Bioorg Med Chem; 2020 Jul; 28(14):115512. PubMed ID: 32616182 [TBL] [Abstract][Full Text] [Related]
33. Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor. Zheng Z; Zhao Z; Li S; Lu X; Jiang M; Lin J; An Y; Xie Y; Xu M; Shen W; Guo GL; Huang Y; Li S; Zhang X; Xie W Mol Pharmacol; 2017 Oct; 92(4):425-436. PubMed ID: 28739572 [TBL] [Abstract][Full Text] [Related]
35. Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts. Fujimori K; Iguchi Y; Yamashita Y; Gohda K; Teno N Molecules; 2019 Nov; 24(22):. PubMed ID: 31744088 [TBL] [Abstract][Full Text] [Related]
36. The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine-rich glycoprotein. Deuschle U; Birkel M; Hambruch E; Hornberger M; Kinzel O; Perović-Ottstadt S; Schulz A; Hahn U; Burnet M; Kremoser C Int J Cancer; 2015 Jun; 136(11):2693-704. PubMed ID: 25363753 [TBL] [Abstract][Full Text] [Related]
37. Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis. Mo C; Xu X; Zhang P; Peng Y; Zhao X; Chen S; Guo F; Xiong Y; Chu XJ; Xu X J Med Chem; 2023 Jul; 66(14):9363-9375. PubMed ID: 37424079 [TBL] [Abstract][Full Text] [Related]
38. Conformational modulation of the farnesoid X receptor by prenylflavonoids: Insights from hydrogen deuterium exchange mass spectrometry (HDX-MS), fluorescence titration and molecular docking studies. Yang L; Broderick D; Campbell Y; Gombart AF; Stevens JF; Jiang Y; Hsu VL; Bisson WH; Maier CS Biochim Biophys Acta; 2016 Dec; 1864(12):1667-1677. PubMed ID: 27596062 [TBL] [Abstract][Full Text] [Related]
39. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. Sepe V; Bifulco G; Renga B; D'Amore C; Fiorucci S; Zampella A J Med Chem; 2011 Mar; 54(5):1314-20. PubMed ID: 21309576 [TBL] [Abstract][Full Text] [Related]
40. Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties. Finamore C; Baronissi G; Marchianò S; Di Leva FS; Carino A; Monti MC; Limongelli V; Zampella A; Fiorucci S; Sepe V Molecules; 2019 Mar; 24(6):. PubMed ID: 30884797 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]